According to Ultragenyx Pharmaceutical's latest financial reports the company has โน13.17 Billion in net assets.
A companyโs net assets is the sum of its assets minus the sum of its liabilities.
Year | Net assets | Change |
---|---|---|
2024-12-31 | $โน22.50 B | -1.86% |
2023-12-31 | $โน22.92 B | -21.4% |
2022-12-31 | $โน29.16 B | -57.52% |
2021-12-31 | $โน68.66 B | -18.66% |
2020-12-31 | $โน84.42 B | 81.09% |
2019-12-31 | $โน46.62 B | 9.5% |
2018-12-31 | $โน42.57 B | 73.9% |
2017-12-31 | $โน24.48 B | -23.98% |
2016-12-31 | $โน32.20 B | -8.74% |
2015-12-31 | $โน35.29 B | 201.1% |
2014-12-31 | $โน11.72 B | 278.63% |
2013-12-31 | $โน3.09 B | -32.96% |
2012-12-31 | $โน4.61 B | 720.2% |
2011-12-31 | $โน0.56 B |
Company | Net assets | differencediff. | Country |
---|---|---|---|
![]() BioMarin Pharmaceutical BMRN | โน504.49 B | 3,730.49% | ๐บ๐ธ USA |
![]() Amicus Therapeutics
FOLD | โน16.85 B | 27.98% | ๐บ๐ธ USA |
![]() Esperion Therapeutics ESPR | -โน37.12 Billion | -381.80% | ๐บ๐ธ USA |
![]() Lexicon Pharmaceuticals
LXRX | โน10.71 B | -18.65% | ๐บ๐ธ USA |